The post TROVE token’s 97% wipeout: From $11.5 mln presale to rug-pull accusations appeared on BitcoinEthereumNews.com. On the 20th of January, the crypto marketThe post TROVE token’s 97% wipeout: From $11.5 mln presale to rug-pull accusations appeared on BitcoinEthereumNews.com. On the 20th of January, the crypto market

TROVE token’s 97% wipeout: From $11.5 mln presale to rug-pull accusations

On the 20th of January, the crypto market was stunned when Trove Market launched its native token, TROVE.

Prior to the launch,  Trove Market had faced community backlash after the team announced it would abandon the Hyperliquid LI blockchain.

This was a massive breach of its social contracts with investors after raising $11.5 million in an ICO presale, setting the ground for a rough launch. 

Trove market accused of rug pull

The TROVE token launched on Trove’s Perp DEX, with a fully diluted valuation of $20 million. Shortly after launch, the token’s FVD plummeted 97.5% to $500k, then rose slightly to $722.8k at press time. 

At the same time, its market cap dropped from $612k to $512k, a loss of nearly $100k, indicating capital outflows. 

Source: CoinGecko

Soon after the TROVE token went live, it dumped 28% in minutes from $0.0006 to $0.00043 before attempting a recovery. 

Since then, the altcoin price rose to $0.00078 before slightly retracing to $0.00072, marking an 18% rise on the daily timeframe. 

Reasons why TROVE was doomed to fail

In preparation for the token launch, developers ran an ICO on Hyperliquid. The team managed to surpass its $2.5 million target and raised over $11.5 million. 

After raising these funds, the team announced it will keep $9.3 million to build its Solana-based Perp DEX. The move was perceived as the first red flag, and the team faced fierce community backlash. 

Even worse, the community accused Trove Market of paying KOLs for promotion, with funds flowing to entertainment addresses. 

According to Hyperliquid Daily, waleswoosh alone pocketed $8K for pumping and promoting the token. ZachXBT dug up receipts showing ICO money funneled straight to casinos and Polymarket bets.

Source: Hyperscan

The last nail in the coffin was driven by the alleged liquidity provider. Days ago, a key liquidity partner lost confidence in the project and liquidated 500k HYPE worth approximately $12.9 million.

The decision to sell these Hype tokens effectively pulled the rug from under Trove’s operational requirements, forcing the team to seek support elsewhere.

With these factors combined, the TROVE token sat as a ticking time bomb, and the launch validated the community’s fears.

Will TROVE see more losses?

TROVE plummeted as negative sentiment had taken hold even before the token launch. As such, earlier buyers rushed to dump, fearing making more losses.

Despite that, most of the presale buyers recorded massive losses. For instance, an earlier buyer argued that his $20k investment should have resulted in $14k in USDC and $6k in TROVE.

Source: Fantardio on X

However, the buyers received $600, blaming the token’s GIGA nuking. With market sentiment even more bearish, TROVE is at risk of further losses.

If current sentiment persists, the token will plummet to $0.0004. However, if the team can manage to restore community confidence, $0.001 is within reach.


Final Thoughts

  • Trove Market is accused of a rug pull, following a contentious launch of the TROVE token on Solana Perp DEX. 
  • TROVE FVD dropped 97.5% from $20 million to $500k, warning of liquidity exit. 
Next: CLARITY Act: Hoskinson questions Ripple CEO’s ‘better than no clarity’ remark

Source: https://ambcrypto.com/trove-tokens-97-wipeout-from-11-5-mln-presale-to-rug-pull-accusations/

Market Opportunity
Melon Logo
Melon Price(MLN)
$4.595
$4.595$4.595
+0.37%
USD
Melon (MLN) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26